Thomson Reuters investment banking scorecard

Thomson Reuters Logo

· Global DCM activity totals $3.3tril, up 5% compared to YTD 2013

· Europe M&A increases 112% compared to last year

· Asia Pacific IPOs hit $32.2bn so far in 2014, more than double year-ago levels

· Citi is biggest mover for WW M&A advice, up five spots to #4 compared to 2013

With an increase of four spots, Bank of America is biggest mover for global ECM to #2

· HSBC moved three spots to #5 as biggest mover for global DCM

· Archer Daniels Midland's $3.1bn bid for Switzerland's Wild Flavors GmBH pushed the level of cross-border M&A to $717.9bn for year-to-date 2014, more than double last year's activity levels and the strongest year-to-date period for cross-border deal making on record. The United States accounts for 19% of cross-border targets and 29% of cross-border acquirors. Purchases by US-based companies in Europe total $167.8bn so far this year- an all-time record for any year-to-date period.

· UK companies have raised $17.7bn in the initial public offering market so far this year, the most ever for any year-to-date period since records began in 1980. SSP Group Plc's $826.3m offering ranks as the sixth largest IPO from a UK company this year and ranks as the all-time largest UK food & beverage retail IPO. JP Morgan tops the list of UK IPO underwriters with 12.2% market share for year-to-date 2014, down from 18.8% market share a year ago, when the firm also ranked first.

· AIG's $2.5bn investment grade debt offering pushes investment grade corporate debt offerings from US companies to $442.4bn for year-to-date 2014, a 9% increase compared to a year ago. This week's offering from AIG marks the largest debt offering from the company since August 2008.

· M&A activity involving Swiss companies hit $118.1bn this week with the $1.7bn combination of domestic insurers Helvetia and Nationale Suisse and the $3.1bn tie-up of Wild Flavors and Archer Daniels Midland. Several multi-billion dollar transactions including Holcim's $39.5bn offer for LaFarge and the sale of GlaxoSmithKline's Oncology unit to Basel-based Novartis for $16.0bn have pushed deal making levels in the country to the third highest year-to-date on record.

Source - Thomson Reuters 

Best place to workThe Best Firm of the Last Decade is...

Register for Financial Markets News Alerts